On January the 25th, Zymeworks announced the opening of their new state-of-the-art laboratory in Vancouver, Canada. The company, which is solely dedicated to discovery and development of next-generational multi-functional biotherapeutics. At this point in time, the company is focused on developing treatments for cancer. Their new 10,000 square foot lab facility in Vancouver, Canada will undoubtedly be a valuable asset for their company. The company hopes the new lab will give them additional control over discovery research, antibody generation, and the creation of multi-functional proteins.
As pointed out by the company’s President and CEO, Dr. Ali Tehrani, the lab will allow Zymeworks to conduct their own internal research and development in a totally integrated manner. The clinical-stage biopharmaceutical company’s lead candidate is ZW25. The effectiveness of the novel bispecific antibody is currently being studied in an adaptive Phase 1 clinical trial. The company has also been working diligently to establish a pipeline of preclinical product candidates, as well as discovery-stage programs for immuno-oncology and other areas. To learn more about Zymeworks and their pipeline, be sure to check out their official website at www.zymeworks.com.